Charles Schwab Investment Management Inc. Sells 58,989 Shares of Quanterix Co. (NASDAQ:QTRX)

Charles Schwab Investment Management Inc. cut its holdings in shares of Quanterix Co. (NASDAQ:QTRX - Free Report) by 18.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 266,615 shares of the company's stock after selling 58,989 shares during the period. Charles Schwab Investment Management Inc. owned about 0.69% of Quanterix worth $2,834,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Portolan Capital Management LLC increased its stake in shares of Quanterix by 31.4% in the third quarter. Portolan Capital Management LLC now owns 2,520,686 shares of the company's stock valued at $32,668,000 after buying an additional 602,656 shares during the period. Geode Capital Management LLC boosted its holdings in Quanterix by 2.2% in the third quarter. Geode Capital Management LLC now owns 858,667 shares of the company's stock valued at $11,131,000 after acquiring an additional 18,231 shares during the last quarter. State Street Corp boosted its holdings in Quanterix by 2.2% in the third quarter. State Street Corp now owns 836,443 shares of the company's stock valued at $10,840,000 after acquiring an additional 18,050 shares during the last quarter. Pier Capital LLC increased its position in Quanterix by 23.5% during the 3rd quarter. Pier Capital LLC now owns 511,798 shares of the company's stock valued at $6,633,000 after purchasing an additional 97,256 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Quanterix by 28.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 217,957 shares of the company's stock worth $2,825,000 after purchasing an additional 47,873 shares during the last quarter. 86.48% of the stock is owned by institutional investors.

Remove Ads

Quanterix Stock Performance

Shares of Quanterix stock traded down $0.05 on Monday, reaching $6.51. 485,465 shares of the company's stock were exchanged, compared to its average volume of 514,668. The company has a market capitalization of $252.43 million, a P/E ratio of -6.14 and a beta of 1.33. Quanterix Co. has a 52 week low of $6.14 and a 52 week high of $23.86. The firm's 50-day moving average is $7.94 and its two-hundred day moving average is $10.59.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its earnings results on Monday, March 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.03). Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. The company had revenue of $35.16 million for the quarter, compared to the consensus estimate of $34.93 million. On average, analysts expect that Quanterix Co. will post -0.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on QTRX shares. Scotiabank reiterated an "outperform" rating on shares of Quanterix in a research report on Tuesday, March 25th. Canaccord Genuity Group decreased their price target on Quanterix from $20.00 to $15.00 and set a "buy" rating for the company in a report on Tuesday, March 18th.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.